Evidence map›Paper›PMID 42415595›Full record

ReviewObesity (Silver Spring, Md.)2026

Glucagon-Like Peptide-1 Receptor Agonist-Based Agents and Body Composition: Filling More Gaps.

Robert L Dubin, Tierra N Sanders, Hunter M Schwab, Steven B Heymsfield, Frank L Greenway

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Obesity (Silver Spring, Md.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Robert L DubinPennington Biomedical Research Center, Louisiana State University Health Sciences, Baton Rouge, Louisiana, USA.ORCID https://orcid.org/0000-0002-7378-9650
Tierra N SandersPennington Biomedical Research Center, Louisiana State University Health Sciences, Baton Rouge, Louisiana, USA.
Hunter M SchwabPennington Biomedical Research Center, Louisiana State University Health Sciences, Baton Rouge, Louisiana, USA.
Steven B HeymsfieldPennington Biomedical Research Center, Louisiana State University Health Sciences, Baton Rouge, Louisiana, USA.ORCID https://orcid.org/0000-0003-1127-9425
Frank L GreenwayPennington Biomedical Research Center, Louisiana State University Health Sciences, Baton Rouge, Louisiana, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The last 2 decades have seen historic advances in the treatment of obesity. We are entering an era of defining obesity not by weight-based outcomes but by changes in body composition. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are forming the platform for obesity treatments based on their high level of efficacy. Body composition can be quantified by changes in percent fat/fat-free mass as a total of body weight. The amount of weight that is lost as % fat-free mass (% FFML) with diet-induced weight loss is ~25% but is extremely variable. Our aim was to provide an update to our previous report assessing changes in body composition using GLP-1 RA-based agents. In our updated review of 40 DXA-based reports, we found the mean (SD) % FFML was 29.1% (19.0%). Similar to our previous report, we found that the changes in body composition using these agents remain in the upper range of expected % FFML using other nonsurgical interventions for obesity. Functional measures of strength and performance and assessing body composition effects of future GLP-1-based agents are needed to understand the continued gaps that exist in determining the impact these treatments have, particularly in high-risk populations.

Indexed as

Anti-Obesity AgentsBody CompositionGlucagon-Like Peptide-1 Receptor AgonistsObesityExenatideGlucagon-Like Peptide-1 ReceptorHumansLiraglutidePeptidesSemaglutideTirzepatideVenomsWeight LossAnti-Obesity AgentsExenatideGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsLiraglutidePeptidesSemaglutideTirzepatideVenoms

Identifiers

PMID42415595
PMCPMC13535704

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.